ArticleTargeted oncology2024

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.

Makoto Hibino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.